Today MEI Pharma Inc (MEIP) Stock Rises

September 17, 2017 - By Linda Rogers

The stock of MEI Pharma Inc (NASDAQ:MEIP) is a huge mover today! The stock increased 4.17% or $0.11 on September 15, reaching $2.75. About 241,693 shares traded or 4.96% up from the average. MEI Pharma Inc (NASDAQ:MEIP) has risen 20.90% since September 17, 2016 and is uptrending. It has outperformed by 4.20% the S&P500.
The move comes after 8 months positive chart setup for the $97.52M company. It was reported on Sep, 17 by Barchart.com. We have $3.00 PT which if reached, will make NASDAQ:MEIP worth $8.78 million more.

Wall Street await MEI Pharma Inc (NASDAQ:MEIP) to release earnings on November, 14. Analysts forecast EPS of $-0.17, down exactly $0.05 or 41.67 % from 2014’s $-0.12 EPS. After posting $-0.12 EPS for the previous quarter, MEI Pharma Inc’s analysts now forecast 41.67 % negative EPS growth.

MEI Pharma Inc (NASDAQ:MEIP) Ratings Coverage

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. As per Wednesday, August 2, the company rating was maintained by Oppenheimer. The stock of MEI Pharma Inc (NASDAQ:MEIP) has “Buy” rating given on Monday, June 26 by Oppenheimer. Stifel Nicolaus maintained MEI Pharma Inc (NASDAQ:MEIP) on Wednesday, September 6 with “Hold” rating. The rating was maintained by Oppenheimer with “Buy” on Wednesday, May 31. The rating was maintained by Oppenheimer on Wednesday, June 14 with “Buy”. The firm has “Hold” rating given on Friday, September 4 by Wedbush.

More notable recent MEI Pharma Inc (NASDAQ:MEIP) news were published by: Prnewswire.com which released: “MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for …” on September 05, 2017, also Prnewswire.com with their article: “Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation …” published on May 18, 2017, Prnewswire.com published: “MEI Pharma Reports Second Quarter Fiscal Year 2017 Results” on February 08, 2017. More interesting news about MEI Pharma Inc (NASDAQ:MEIP) were released by: 247Wallst.com and their article: “Can MEI Pharma Rise Nearly 300%?” published on May 25, 2017 as well as Nasdaq.com‘s news article titled: “MEI Pharma-Presage Biosciences on License Deal for Voruciclib” with publication date: September 06, 2017.

MEI Pharma, Inc. is an oncology company. The company has market cap of $97.52 million. The Firm is focused on the clinical development of drugs and therapies for treatment of cancer. It has a 41.12 P/E ratio. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.